Darius M. Moshfeghi Email and Phone Number
Darius M. Moshfeghi work email
- Valid
Darius M. Moshfeghi personal email
- Valid
Darius M. Moshfeghi phone numbers
Darius M. Moshfeghi, MD, is Professor of Ophthalmology and Chief of Retina at the Byers Eye Institute, Horngren Family Vitreoretinal Center, Department of Ophthalmology at the Stanford University School of Medicine. My career is focused on preventing blindness in children, particularly newborns and premature infants. This includes partnering with imaging companies, pharmaceutical companies, non-profits, regulatory agencies, professional organizations and hospital networks to develop turnkey, scalable solutions that can be deployed in neonatal intensive care units and newborn wards. I have developed and lead the Stanford telemedicine screening programs for retinopathy of prematurity (ROP), consisting of 2 adminstrative divisions (SUNDROP and TELEROP), covering more than 2.5% of neonatal intensive care units and >3.75% of eligible infants in the U.S. ROP is the leading cause of blindness in children in the U.S. and is treatable with early identification and intervention. We have demonstrated that we can decrease interventions while avoiding adverse anatomic outcomes through a dedicated Telemedicine, Treatment Warranted, and High Intensity Screening approach.I served on the Steering Committee for Regeneron and their BUTTERFLEYE trial of aflibercept, which resulted in the first pharmacologic approval for treatment of ROP in the U.S. in February of 2023. Currently, I am focused on developing pharmacologic preventive strategies for ROP.My extensive experience in telemedicine grading of images has led to numerous positions serving on Data Safety Monitoring Committees for pharmacologic trials (Affamed Therapeutics, Alcon, Chengdu Vanotech, Clinical Trial Research Group, Icon Therapeutics, Insite DME, Novartis).Currently, I am the lead external consultant for the Alexion (division of Astra Zeneca) ONWARD Phase 2 multicenter randomized, placebo-controlled clinical trial of oral anti-Factor D for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).I enjoy conceiving of ideas for clinical practice and then commercializing on these concepts. I am a founder and board member of Pr3vent which is unveiling a universal newborn eye screening platform in the United States and Brazil. I was the Chairman of Placid0 until its acquisition by Ainsly (Waldo) in November 2021. I served on the board of directors for 1-800 Contacts until its acquistion by KKR in November 2020. In 2017, I partnered (through Stanford) with Pediatrix to form the largest telemedicine screening program for ROP in the USA.
Stanford University School Of Medicine
View-
Chief Of Retina Division: Vitreoretinal Surgery And Medical DiseasesStanford University School Of MedicineStanford, Ca, Us
-
Chief Of Retina Division: Vitreoretinal Surgery & Medical DiseasesStanford University School Of Medicine Jul 2017 - PresentPalo Alto, Ca, Us
-
Professor Of Ophthalmology University Medical LineStanford University School Of Medicine Jan 2015 - PresentPalo Alto, Ca, UsI have led the Stanford University Retina Division of the Department of Ophthalmology since 2017. We have a large vitreoretinal surgery program with experts in all subspecialties and fellowship training programs in VR surgery, medical retina, uveitis, and ocular oncology.My area of expertise is retinopathy of prematurity (ROP) screening and treatment techniques with a particular emphasis on incorporating telemedicine screening, diagnosis, monitoring, and therapeutics. I served on the steering committee for Regeneron when aflibercept was given approval by the FDA as the first pharmacologic therapy for ROP in the U.S, and advise numerous companies on their study designs and regulatory pathways. Additionally, I have developed a pediatric progressive myopia (high myopia) practice, evaluating isolated and syndromic cases of progressive myopia and developing strategies for identification, classification, and treatment of this epidemic disease.
-
Founder And Director, Telerop TelemedicineStanford University School Of Medicine Oct 2017 - PresentPalo Alto, Ca, UsPartnership with Pediatrix and Stanford University to provide telemedicine screening for ROP across the United States.
-
Founder And Director, Sundrop Telemedicine NetworkStanford University School Of Medicine Oct 2005 - PresentPalo Alto, Ca, Us
-
Chief Of Pediatric Vitreoretinal Surgery & Medical DiseasesStanford University School Of Medicine Jan 2011 - Feb 2023Palo Alto, Ca, Us
-
Founder And Director Of Vitreoretinal Surgery & Medical Diseases FellowshipStanford University School Of Medicine Mar 2009 - Jan 2018Palo Alto, Ca, Us
-
Director Of Ophthalmic TelemedicineStanford University School Of Medicine Jan 2011 - Dec 2017Palo Alto, Ca, Us
-
Associate Professor Medical School LineStanford University School Of Medicine Jul 2009 - Dec 2014Palo Alto, Ca, Us
-
Co-Director Of Ocular OncologyStanford University School Of Medicine Jul 2008 - Jun 2011Palo Alto, Ca, Us
-
Assistant Professor Medical School LineStanford University School Of Medicine Jul 2002 - Jun 2009Palo Alto, Ca, Us
-
Director Of Ocular OncologyStanford University School Of Medicine Jul 2002 - Jun 2008Palo Alto, Ca, Us
-
Member Board Of DirectorsGigcapital Global Aug 2024 - PresentPalo Alto, Ca, UsGigCapital7 -
Independent Medical Monitor, Rescue Therapy, Sol TrialOcular Therapeutix, Inc. Apr 2024 - PresentBedford, Ma, UsAlong with Barry Kupperman MD, I serve to evaluate rescue therapy interventions as an independent medical monitor arising from Principal Investigators of the SOL trial of tyrosine kinase inhibitors vs aflibercept. We engage with the individual PI when a rescue therapy is proposed to assess patient risk and adherence to protocol recommendations. -
Chair, Data Safety Monitoring BoardOsanni Bio Feb 2024 - Present -
Chair, Data Safety Monitoring BoardTreat & Extend Versus Fixed Dosing With Faricimab For Of Diabetic Macular Edema: Insite-Dme Jul 2023 - PresentMcMaster University
-
Data Monitoring CommitteeVanotech Chengdu Kanghang Apr 2023 - PresentMember of the Data Safety Monitoring Committee for VAN-2201
-
Co-Founder, Board Of DirectorsPr3Vent Inc Sep 2017 - PresentPalo Alto, California, Ushttps://www.pr3vent.com/We have partnered with to launch universal newborn eye screening in the USA in Redwood City, California. -
Senior ConsultantAlexion Pharmaceuticals, Inc. Apr 2020 - PresentBoston, Massachusetts, UsIn my role as Senior Consultant (Ophthalmology) for Alexion, I helped design the ONWARD Phase II clinical trial for danicopan oral anti-complement Factor D for treatment of geographic atrophy secondary to age-related macular degeneration. I have been involved in the trial design, site evaluations, regulatory interactions with the FDA and EMA, as well as outcome determination. I recruited the scientific advisory board and vetted the image reading centers. I also oversaw development of their microperimetry testing and evaluation approaches. -
Editor In ChiefOphthalmic Surgery, Lasers And Imaging Retina Jul 2017 - PresentIn 2016, I assumed the duties of Acting Editor-in-Chief and in that capacity have worked with the the Managing Editor, and the Editorial Board to continue the transformation of OSLI-Retina to a premier destination for innovative vitreoretinal technology, imaging, and therapeutic manuscripts. I have added seven Associate Editors:-Rishi Singh, MD, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH-Kimberly Drenser, MD, PhD, Associated Retinal Consultants, Royal Oak, MI-Theodore Leng, MD, Byers Eye Institute, Stanford University, Palo Alto, CA-Demetrios Vavvas, MD MEEI, Harvard University, Cambridge, MA-John Miller, MD, MEEI, Harvard University, Cambridge, MA-Eleanor "Nora" Lad, MD, Duke University, Durham, NC-Margaret Greven, MD, Wake Forest, Winston Salem, NCAdditionally, we recently added Avni Finn Patel, MD, Vanderbilt, Nashville, TN, as Executive Deputy Editor.We recently institute and anonymized reviewer process in order to minimize bias against authors during reviews.
-
Acting Editor In ChiefOphthalmic Surgery, Lasers And Imaging Retina Jul 2016 - Jul 2017
-
Deputy Editor In ChiefOphthalmic Surgery, Lasers And Imaging Retina Jan 2013 - Jul 2016
-
Editorial BoardOphthalmic Surgery, Lasers And Imaging Retina Jan 2010 - Jan 2013
-
Founding Member Rop SectionCollaborative Community On Ophthalmic Imaging Sep 2019 - PresentThe ROP subsection is headed by Dr. Michael Chiang and includes pediatric retina specialists, pediatric ophthalmologists, and AI/DL experts with the purpose of developing consensus standards for the application of AI/DL for ROP, the leading cause of treatable blindness in children in the United States.
-
MemberStartx. Oct 2019 - PresentPalo Alto, California, UsFall 2019 Class. Pr3vent, a StartX company, is part of a community of Stanford's top Tech and MedTech entrepreneurs solving real world problems. -
Executive EditorAmerican Journal Of Ophthalmology Jan 2017 - PresentIn my role as Executive Editor, I evaluate vitreoretinal articles for publication worthiness, identify reviewers, and assist the Editor-in-Chief, Dr. Richard K. Parrish, II in identifying potential new areas for editorial content.
-
Editorial BoardAmerican Journal Of Ophthalmology Apr 2016 - Jan 2017
-
Director, Board Of DirectorsDsentz, Inc. Nov 2016 - Present
-
Co-FounderDsentz, Inc. Nov 2016 - Present
-
Chief Medical AdvisorWaldo Nov 2021 - Jul 2024New York, UsI joined the Waldo team following the acquisition of Placid0. Waldo is focused on advancing eye health by providing consumers and eye care providers access to innovative, accessible, and affordable contact lenses and eye care products.In my role as Chief Medical Advisor, I led the development of the Waldo CLEA portable keratometer technology system to bridge the gap between consumers and their eye care providers. -
Chairman, Co-FounderPlacid0, Inc. Aug 2020 - Nov 2021Placid0 was acquired by WALDO in November 2021 for its mobile platform for assessing ocular conditions that will improve connectivity and communication between patients & consumers and their eye care professionals. -
Director, Board Of Directors1-800 Contacts Mar 2017 - Nov 2020Draper, Utah, UsI was recruited to serve as an independent director who provided knowledge and insight into telemedicine in eye care, eye care professionals (ECP), regulatory pathways, and to serve as a bridge between the ophthalmology community and 1-800 Contacts. I advised on their telemedicine strategy with ECP and also aided in assessment of new technologies. My term ended with the acquisition by KKR. 1-800 Contacts is an amazing organization led by an astute, accomplished and visionary management team with keen insight into consumer needs and directionality of the market and is positioned to be an impactful force in the consumer eye care market for years. I truly enjoyed my tenure on the board. -
Data Monitoring CommitteeNovartis Jan 2019 - Aug 2020Basel, Baselstadt, ChServed on the DMC, the Program-Level DMC, and the Safety Review Committee for RTH258 (brolucizumab) for the following indications and clinical trials,:DMC for Diabetic Retinopathy and Edema–KITE–KESTRELDMC for Neovascular AMD–CHINADMC for Neovascular AMD, non-näive–MERLINDMC for Retinal Vein Occlusion–RAPTOR–RAVENProgram-Level DMC for RTH258 for the following programs:–RAPTOR–RAVEN–KITE–KESTREL–HOBBY–KINGLET–MERLIN–TALON–KINGFISHERSafety Review Committee for Brolucizumab HAWK/HARRIER, Post-marketing Events -
Data Monitoring CommitteeAlcon 2015 - Dec 2018Geneva, Switzerland, ChServed on the DMC for Neovascular AMD for RTH258–HAWK–HARREIR -
Lead Ophthalmology ConsultantOraya Therapeutics, Inc. 2007 - 2014Newark, Ca, UsOraya Therapeutics, Inc., is a Bay Area medical device start-up company that has developed a novel stereotactic radiation delivery system for the treatment of wet age-related macular degeneration. I have been with the company since the original design phase. In my capacity as the chief ophthalmology adviser, I have performed the following tasks:•aided in the design and testing of the eye guide device•aided in the design and implementation of two non-human safety trials•participated and designed the in vitro testing and validation of the robotically-controlled delivery and targeting system•participated in 2 rounds of venture funding•designed, recruited the vitreoretinal physicians, and oversaw the implementation of the Phase I safety trial of the x-ray irradiation device in Mexico City•identified and recruited the members of the Scientific Advisory Board, the external Data Safety Monitoring Board, and the Reading Centers•represented the company in multiple interactions with the Food and Drug Administration•aided in the design, implementation, and oversight of the successful Phase II multicenter randomized controlled double-masked INTREPID clinical trial that demonstrated a statistically significant decrease in the number of treatments for wet AMD•oversaw the publication strategy that has resulted in over 10 peer-reviewed publications on the clinical application of the technology -
Editor, Retina SectionCompare Networks, Inc., Ophthalmology Web 2007 - 2008Ophthalmology Web is an online portal that attempts to serve as a one-stop shop for all things ophthalmological. This can include equipment purchases, equipment evaluations, meeting organizer, and discussion forum for topics (timely, controversial, and review). In my position as the original Editor of the Retina Section, I performed the following tasks:•organized retina content for the ophthalmologyweb.com website, •identified key thought leaders for video interviews•recruited editors for the other Ophthalmology subspecialties (cataract, refractive, glaucoma, 2 associate editors of Retina)•provided monthly articles of interest to the retina community•developed presentations on retina topics for distribution to the retina community
Darius M. Moshfeghi Skills
Darius M. Moshfeghi Education Details
-
Cole Eye Institute, Cleveland ClinicVitreoretinal Surgery -
The University Of Tennessee Health Science CenterOcular Oncology & Orbital Disease
-
Tulane University School Of MedicineOphthalmology
-
Tulane University School Of MedicineTransitional Medicine
-
Tulane University School Of MedicineMedicine
-
Tulane UniversityBiomedical Engineering
Frequently Asked Questions about Darius M. Moshfeghi
What company does Darius M. Moshfeghi work for?
Darius M. Moshfeghi works for Stanford University School Of Medicine
What is Darius M. Moshfeghi's role at the current company?
Darius M. Moshfeghi's current role is Chief of Retina Division: Vitreoretinal Surgery and Medical Diseases.
What is Darius M. Moshfeghi's email address?
Darius M. Moshfeghi's email address is dm****@****ail.com
What is Darius M. Moshfeghi's direct phone number?
Darius M. Moshfeghi's direct phone number is +165049*****
What schools did Darius M. Moshfeghi attend?
Darius M. Moshfeghi attended Cole Eye Institute, Cleveland Clinic, The University Of Tennessee Health Science Center, Tulane University School Of Medicine, Tulane University School Of Medicine, Tulane University School Of Medicine, Tulane University.
What are some of Darius M. Moshfeghi's interests?
Darius M. Moshfeghi has interest in Electronics, Kids, Investing, Reading.
What skills is Darius M. Moshfeghi known for?
Darius M. Moshfeghi has skills like Clinical Trials, Surgery, Clinical Research, Medical Devices, Medicine, Medical Imaging, Ophthalmology, Medical Education, Healthcare, Commercialization, Biotechnology, Hospitals.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial